retatrutide triple agonist gip glp-1 glucagon phase 3 2025 A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology retatrutide triple agonist glp-1 gip

For example, in July, CVS Caremark, a pharmacy-benefit manager hired by insurance companies to help determine which drugs to cover, began recommending Wegovy over Zepbound in most cases

This is just one of the many potential benefits that this drug has been associated with, and more doctors are prescribing Semaglutide for weight loss purposes today

Williams, C.A., et al

By clicking Accept, you consent to the use of ALL the cookies.

At the highest dose (3/6/9/12 mg escalation scheme), mean HbA1c was reduced by up to 1.6% and weight by nearly 9 kg, which was significantly greater than placebo

Clinicians should therefore remain alert to emerging updates and apply flexible, evidence-based approaches